Katalytic Therapeutics Inc. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a phosphodiesterase PDE4-targeting ...
In addition, the Group's subsidiary Viva Biotech Shanghai was successfully restructured into a joint stock limited company on September 27, 2024, as the Group currently holds approximately 72.9% of ...
PROTAC compounds are designed to bind to a target protein and recruit an E3 ubiquitin ligase, tagging the target for degradation by the proteasome. These compounds enable the selective removal of ...
The drug in question, called vepdegestrant, is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. The phase 3 study assessed vepdegestrant against AstraZeneca’s hormone med Faslodex in ...
Neuroblastomas are the most common cancer in infants, with about 700–800 diagnoses per year in the US, according to the American Cancer Society. Some of the most high-risk cases are driven by ...
The 67th E3 Saxo Bank Classic kicks off a week of fever pitch action in Belgium that culminates in the Tour of Flanders on April 6th. Set on the same roads over much of the same climbs ...
Mathieu van der Poel decimates peloton across Flemish cobbles for repeat victory at E3 Saxo Classic / How it unfolded For a second year in a row, Mathieu van der Poel (Alpecin-Deceuninck ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback